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In cancer, Transforming Growth Factor b (TGFb) increases proliferation and promotes invasion via selective loss of signalling
pathways. Oesophageal adenocarcinoma arises from Barrett’s oesophagus, progresses rapidly and is usually fatal. The
contribution of perturbed TGFb signalling in the promotion of metastasis in this disease has not been elucidated. We therefore
investigated the role of TGFb in Barrett’s associated oesophageal adenocarcinoma using a panel of cell lines (OE33, TE7, SEG,
BIC, FLO). 4/5 adenocarcinoma cell lines failed to cell cycle arrest, down-regulate c-Myc or induce p21 in response to TGFb, and
modulation of a Smad3/4 specific promoter was inhibited. These hyperproliferative adenocarcinoma cell lines displayed a TGFb
induced increase in the expression of the extracellular matrix degrading proteinases, urokinase-type plasminogen activator
(uPA) and plasminogen activator inhibitor 1 (PAI-1), which correlated with an invasive cell phenotype as measured by in vitro
migration, invasion and cell scattering assays. Inhibiting ERK and JNK pathways significantly reduced PAI and uPA induction
and inhibited the invasive cell phenotype. These results suggest that TGFb Smad-dependent signalling is perturbed in Barrett’s
carcinogenesis, resulting in failure of growth-arrest. However, TGFb can promote PAI and uPA expression and invasion through
MAPK pathways. These data would support a dual role for TGFb in oesophageal adenocarcinoma.
Citation: Onwuegbusi BA, Rees JRE, Lao-Sirieix P, Fitzgerald RC (2007) Selective Loss of TGFb Smad-Dependent Signalling Prevents Cell Cycle Arrest
and Promotes Invasion in Oesophageal Adenocarcinoma Cell Lines. PLoS ONE 2(1): e177. doi:10.1371/journal.pone.0000177
INTRODUCTION
Transforming Growth Factor b (TGFb), and the components of its
signal transduction pathway, are known to demonstrate tumour
suppressor activity. In many human cancers, there are inactivating
mutations in components of the TGFb pathway resulting in
uncontrolled proliferation. In addition, through its actions on both
the tumour cells and the surrounding stromal cells, TGFb can
enhance invasion, motility and metastasis. TGFb can thus play
a dual role in the initiation and malignant progression of human
cancer [1,2].
TGFb signalling occurs through activation of type I and II
trans-membrane serine/threonine kinase receptors, which leads to
the phosphorylation of Smad 2 and 3. This complex, in association
with Smad 4 translocates to the nucleus resulting in transcriptional
activation of downstream targets [3]. The anti-proliferative effects
of TGFb in normal epithelial cells are achieved through the
inactivation of cyclin dependent kinases (cdk) 2, 4 and 6, which
lead to cell cycle arrest. This is mediated by the rapid induction
of the cdk4/6 inhibitor p15
INK4B, and the cdk2 inhibitor
p21
CIP1/WAF1. Another key event in TGFb mediated cell cycle
arrest involves the repression of c-Myc. This transcription factor
binds the promoters of p15
INK4B and p21
CIP1/WAF1 and suppresses
their expression [4]. Rapid transcriptional down-regulation of
c-Myc by TGFb relieves this repression, allowing binding of the
heteromeric Smad complex [5]. The net effect of this is to halt the
cell cycle in G1, and thus potently inhibit proliferation [6].
TGFb is frequently overexpressed by epithelial cancer cells
which become unresponsive to its anti-proliferative effects and this
leads to paracrine stimulation of stromal cells within the tumour
microenvironment [6]. As a result there is stimulation of angio-
genesis and upregulation of extracellular matrix (ECM) degrading
proteinases. Expression of the urokinase-type plasminogen activa-
tor (uPA) is upregulated by TGFb [7], which through the
formation of plasmin enables the tumour cell to penetrate the
basement membrane. Overexpression of uPA has been observed
in invasive malignancies of the breast, colon and stomach [8]. The
uPA inhibitor plasminogen activator inhibitor 1 (PAI-1) is another
TGFb target gene that is up-regulated in advanced cancers [8].
The paradox of an elevated expression level of PAI promoting
tumour invasion is partially explained by the observation that this
inhibitor can promote cell migration and angiogenesis, indepen-
dent of the effects on plasmin activity [9,10].
In contrast to the plethora of information about mutations in
the TGFb signal cascade in colon, gastric and pancreatic cancers
[2,11–13], the contribution of perturbed TGFb signalling in
oesophageal adenocarcinoma has not been elucidated completely.
Oesophageal adenocarcinoma usually arises through a multi-step
sequence from Barrett’s metaplasia to dysplasia and carcinoma
[14]. Recent in vivo and in vitro evidence suggests that inactivation
of SMAD4, lack of RUNX3 and inability to degrade SnoN may
be some of the causes for the unresponsiveness of oesophageal
cancer to TGFb anti-proliferative effect [15–17]. This therefore
begs the question whether TGFb can promote invasion in this
disease in the context of deranged SMAD4 signalling.
The signalling pathways by which TGFb exerts its effects on
migration and invasion are gradually being elucidated. The
activated TGFb receptor complex is now known to activate kinase
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shown to stimulate the expression of both uPA and PAI [18–20].
These pathways include the phosphoinositol-3 kinase (PI3K)[9],
and the mitogen activated protein kinases (MAPK) particularly
extracellular signal regulated kinase (ERK),[21] c-jun N-terminal
kinase (JNK) [22], and p38 [23].
The specific aims of this study were therefore: 1). To determine
whether TGFb can simultaneously affect proliferation (cell cycle,
c-Myc and p21 expression) and invasion indices (ECM proteinase
expression and functional invasive characteristics) in oesophageal
adenocarcinoma cell lines; 2). To elucidate the cell signalling
pathways involved in these responses.
RESULTS
Lack of anti-proliferative response to TGFb
First, the effect of TGFb on cell cycle progression and expression
of cell cycle associated genes, p21 and c-myc, was assessed. The
control experimental conditions were cells treated with serum free
media (SF), which is known to induce cell cycle arrest, and cells
treated with SF media followed by release into the cell cycle by
complete media (C), (Figure 1A and 1B). All cells maintained in
serum free media for 24 h demonstrated an increase in the
proportion of cells in G0/G1 (Figure 1A, 1B). The cells were also
arrested by stimulation with UV light as determined by a BrdU
incorporation assay (data not shown). However, when cultured in
the presence of TGFb (T) only 1/5 BE adenocarcinoma cell lines
(OE33), exhibited an increase in the fraction of cells in G0/G1
(11% OE33 p,0.05), (Fig 1A, 1B). Since the inhibition of prolifer-
ation in response to TGFb would be expected to occur as a result
of an up-regulation of p21
CIP/WAF1 and a decreased expression of
c-Myc, the effect of TGFb on these mRNA expression levels was
examined. Real time PCR demonstrated that only OE33 cells
exhibited a significant increase in p21 and decrease in c-Myc
expression (Figure 2A and 2B), (p,0.05 in both cases). TGFb is
thus unable to significantly alter the expression of c-myc and p21
mRNA, and halt cell cycle progression in 4/5 BE invasive
adenocarcinoma cell lines. This is in keeping with our previous
data on cell proliferation measured using the MTT assay [17].
Impaired Smad-dependent transcriptional
regulation
Nuclear translocation of Smad 2/3 (Fig 3A) and phosphorylation
of Smad 2 and 3 (Fig 3B) were observed in all cell lines following
stimulation with TGFb. Nuclear accumulation of Smad2/3 in
BIC, which does not express Smad4, confirms early work suggest-
ing that Smad4 is not necessary for Smad 2/3 nuclear trans-
location [3]. The nuclear translocation of Smad 2/3 and of the
phosphorylation of Smad 2 and 3 attest to the functionality of the
TGFb pathway. However, the cells remain unable to decrease
their proliferation as a result of TGFb stimulation. Therefore, to
determine whether the inability of TGFb to regulate the cell cycle
is secondary to a lack of Smad dependent transcriptional regula-
tion we used a (CAGA)12-luciferase reporter. The lack of Smad 4
expression in BIC makes this cell line the perfect negative control
for transcriptional regulation of the TGFb pathway. BIC and SEG
both display no transcriptional activity while the low transcrip-
tional activity in TE7 and FLO may not be sufficient to trigger
an anti-proliferative response. Only the TGFb responsive cells,
OE33, demonstrated a marked induction of transcriptional activity
in TGFb treated cells compared to control cells (Figure 3C)
(6865.5; p,0.01). Hence, the non-responsiveness to the anti-
proliferative effects of TGFb may be due, at least partly, to a lack
of Smad-dependent transcriptional regulation, which might stem
from Smad4 inactivation, the inability to degrade SnoN and
possibly other unknown mechanisms [16,17].
MAPK dependent TGFb induction of genes
associated with ECM regulation
The ability of TGFb to regulate the genes uPA and PAI, which are
associated with ECM modulation, was then assessed. All cell lines,
with the exception of BIC up-regulated either PAI and/or uPA in
response to TGFb. (Figure 4A and 4B; OE33, FLO p,0.001;
TE7, SEG p,0.05 for PAI and OE33, SEG, FLO p,0.01; TE7,
p,0.05 for uPA). TGFb was thus able to up-regulate the
expression of both genes associated with ECM modulation in 4/
5 cell lines, including three lines (TE7, SEG and FLO) that lacked
Smad-dependent transcriptional responses and growth suppression
by TGFb.
To characterise the molecular basis for the differential responses
of the cell lines to TGFb, we analysed some of the Smad
independent kinase pathways known to activate genes associated
with ECM.[22] Overall, the levels of phosphorylated JNK did not
vary following TGFb treatment (Figure 5). The levels of phos-
phorylated Akt and ERK1/2 were increased in TE7 (1.6 and 5.3
fold respectively) and SEG (1.7 and 1.8 fold respectively) following
4 hours of stimulation with TGFb (Figure 5 and Figure S1 shows
densitometry data). Only pAKT was increased in OE33 (1.8 fold)
following treatment but very little variation was observed in BIC
and FLO (figure S1). There was no change in total expression
levels of these kinases (data not shown). BIC cells did not show an
Figure 1. Effect of TGFb on cell cycle progression. All cells were
synchronised overnight in serum free media. Cells were then released
into cell cycle by complete media (C), or kept continuously in serum
free media (SF), or in complete media with TGFb (10 ng/mL), all for
24 hours. DNA content was then assessed by flow cytometry. (A)
Representative FACScan profiles for OE33 and FLO. The initial peak
represents the G0/G1 fraction, whilst the second peak represents G2M
fraction. (B) Summary of cell cycle distribution for each cell line
analysed. Each bar represents mean percentage of total cell population
in G0/G1 (grey), S (black) and G2/M (white) phase of the cell cycle from
three separate experiments. * p,0.05, *** p,0.001
doi:10.1371/journal.pone.0000177.g001
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and were therefore not studied further.
Inhibition of PI3Kactivity by LY294002 resulted in a variable
effect on PAI expression (Fig. 6A). Specifically, in OE33 and SEG,
TGFb induced up-regulation of PAI mRNA was significantly
diminished by LY294002 (OE33, SEG p,0.001). Inhibition of
ERK activity by PD98059 significantly diminished TGFb induced
up-regulation of PAI mRNA in all cell lines (OE33, TE7 p,0.05;
SEG p,0.001; FLO p,0.01), (Figure 6A). Following inhibition of
JNK activity by SP600125 there was a reduction of the TGFb
induced up-regulation of PAI by a minimum of 50% in all cell
lines analysed (p,0.05 for all cell lines). These findings were
generally confirmed for a second of each class of kinase inhibitor
(wortmannin, U0126 and Curcumin), (table S1), although ERK
inhibition with UO126 was less effective than PD98059 possibly
because of differential specificity of these inhibitors for MEK1 and
2. A similar pattern was seen when uPA expression was assessed in
inhibitor treated cells (Figure 6B). Whereas, the effects of PI3K
inhibition had a variable effect on uPA expression, inhibition of
ERK by PD98059, and inhibition of JNK by SP600125 markedly
reduced (by a minimum of 40%) the TGFb induction of uPA in all
BE adenocarcinoma cells (Figure 6B). Overall, the most consistent
results were seen with the JNK inhibitors since both inhibitors
(SP600125 and Curcumin) significantly reduced the up-regulation
of PAI and uPA in all cell lines, (table S1).
Next we determined whether inhibition of these kinase path-
ways had an effect on PAI and uPA enzyme activity, as well as
expression levels. Zymography and reverse zymography indicated
that TGFb induces an increase in the proteolytic activity of uPA
(increase in the white band intensity), and an increase in the ability
of PAI to retard the action of uPA in all cells lines analysed
(increase in the dark band intensity), (Fig 7A–D, compare lane C
with T). The inhibition of PI3K activity by LY294002, and inhibi-
tion of ERK signalling by PD98059 resulted in a variable effect on
uPA and PAI activity depending on the cell line (densitometry
given as figure S2). Inhibition of JNK by SP600125 resulted in the
most consistent decrease in activity of uPA and PAI (Figure 7A–D,
compare lane T with SP for each cell line with a variation between
0.1 and 0.5 fold on densitometric analysis, figure S2). The expres-
sion and the enzyme activity data thus suggests that activation of
the ERK and JNK pathways is important for TGFb induced up-
regulation of PAI and uPA in BE adenocarcinoma cells.
TGFb increases invasive cellular properties via
activation of kinase pathways
We determined the ability of TGFb to influence the invasiveness
of cells using three in vitro assays: aggregation, invasion and wound-
ing. An aggregation assay measures the ability of cells to grow in
an anchorage-independent manner; invasion assays through
Figure 2. Regulation of anti-proliferative genes by TGFb in oesophageal cell lines. mRNA expression of p21 (A) and c-Myc (B) was assessed by
quantitative real-time PCR in control cells grown in complete media or in complete media containing 10 ng/mL TGFb for 24 hours. Results for real-
time PCR are expressed as the mean and standard error of four separate experiments relative to b-actin expression. * p,0.05, ***p,0.001
doi:10.1371/journal.pone.0000177.g002
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membrane and to migrate through it while the wounding assay
only measures the ability of cells to migrate to occupy an empty
space. Therefore a highly invasive cell in vitro should not form
aggregates, should migrate through matrigel and to close up
a wound. TGFb had significant effects on at least one assay for
each of the adenocarcinoma cells lines, compared to the control
(no TGFb), (Table 1). In order to examine the effect of kinase
inhibitors these were only used in the cells lines exhibiting an
increase in their invasive phenotype for a particular assay in
response to TGFb.
Therefore, aggregation was performed for TE7, SEG, FLO and
OE33, invasion for TE7, SEG and OE33 and wounding for
OE33. With regards to aggregation, the presence of all three
kinase inhibitors diminished the cell scattering ability (a higher
score denotes less scattering) of TGFb in all the cell lines to
a greater or lesser extent (Figure 8A). The increase in TGFb-
induced invasion observed in TE7, SEG and OE33 cells was
significantly inhibited by LY294002 in TE7 cells (p,0.05), by
SP600125 in SEG (p,0.05) and by all three inhibitors in OE33
(Figure 8B; p,0.001, LY294002; p,0.01, PD98059; p,0.001,
SP600125). In OE33, the TGFb induced increase in wound
healing over 24 h (p,0.05), is significantly diminished by all three
kinase inhibitors (Figure 8C; p,0.05). Overall inhibition of the
JNK pathway with SP600125 had the most consistent effect seen
in SEG, FLO and OE33 in all three of the assays.
DISCUSSION
These data suggest a dual role of TGFb in the regulation of both
the proliferative and invasive properties of BE adenocarcinoma in
vitro. 4/5 BE cell lines are unable to mount an anti-proliferative
response to TGFb. However, the loss of TGFb responsiveness
is selective, such that the same cell lines that fail to exhibit
an anti-proliferative response demonstrate a TGFb dependent
increase in the expression of PAI and uPA via PI3K, ERK and
JNK (Table 2). The effect of kinase inhibitors on expression levels
and the enzyme activity of uPA and PAI suggest that the ERK
and JNK MAPK pathways may play a role. TGFb induced
activation of kinase pathways is functionally significant since
their inhibition results in a reduction of cellular invasive
properties in vitro.
Figure 3. TGFb stimulation of Smad pathway in oesophageal cell lines. Nuclear translocation (A) and phosphorylation (B) of Smad 2/3 following TGFb
stimulation. Cells were treated with 10 ng/mL of TGFb1 for 6 h and Smad 2/3 localisation and phosphorylation were determined by
immunofluorescence using anti-Smad 2/3 antibody and confocal microscopy and western blotting respectively. Regulation of transcription by TGFb
(C). Cells were co-transfected with the (CAGA)12-Luciferase reporter plasmid and the Renilla Luciferase reporter plasmid then incubated, with or
without 10 ng/mL TGFb for 24 h. Data is expressed as mean fold change in CAGA luciferase activity in TGFb samples compared to untreated samples,
normalised to the activity of Renilla, from four separate experiments * p,0.05, ** p,0.01, ***p,0.001
doi:10.1371/journal.pone.0000177.g003
TGFb and Barrett’s Cancer
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be attributed to an inability to down-regulate c-Myc, similar to
breast cancer cells [24]. Given that all of the unresponsive cells in
our panel do not demonstrate a TGFb induced increase in
transcriptional activity of a TGFb reporter plasmid, defective
Smad-mediated signal transduction is a possible underlying
mechanism (Figure 3). However, since the Smad3/4 reporter
construct is not the native promoter and may miss possible
Figure 4. Regulation of ECM modulating genes by TGFb. mRNA expression of PAI-1 (A) and uPA (B) was assessed by quantitative real-time PCR in
control cells and cells treated with 10 mg/mL TGFb for 24 hours. Results for real-time PCR expressed as mean and standard error of four separate
experiments relative to b-actin expression. * p,0.05, ** p,0.01, ***p,0.001
doi:10.1371/journal.pone.0000177.g004
Figure 5. TGFb modulation of kinase pathways in BE adenocarcinoma cells. Western blot on lysate from OE33, TE7, SEG, BIC and FLO cells treated with
control media (2) or media with 10ng/mL TGFb (+) for 4 hours for phosphorylated ERK1/2, phosphorylated JNK or phosphorylated Akt.
Immunoprecipitation was performed with total antibody for Akt, ERK and JNK, and then blots were probed with the phosphorylated antibody.
doi:10.1371/journal.pone.0000177.g005
TGFb and Barrett’s Cancer
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interpreted with caution. Furthermore, other mechanisms such
as the inability to degrade SnoN have been described in
oesophageal cells as a possible reason for a lack of responsiveness
to TGFb [16].
In contrast, there was a modest TGFb dependent activation of
kinase pathways (PI3K, ERK and JNK MAPK) in BE adenocar-
cinoma cells (Figure 5). This is interesting since inhibition of PI3K,
ERK and JNK MAPK decreased the TGFb induced expression of
the ECM genes PAI and uPA (Figure 6). The PAI promoter
contains motifs complementary to the binding sequence of AP-1
Figure 6. Effect of inhibition of PI3K, ERK and JNK pathways on PAI and uPA expression. Quantitative real-time PCR showing PAI (A) and uPA (B)
expression in cells treated with 10 ng/mL TGFb and PI3K inhibitor LY29004 (LY, 20 mM); ERK inhibitor PD98059 (PD, 10 mM); and JNK inhibitor
SP600125 (SP, 10 mM) for 24 hours. Results are expressed as a percentage of expression in inhibitor treated samples compared to TGFb treated
samples, such that the greater the inhibition the lower the percentage expression. Results are mean and standard error of four separate experiments.
*p ,0.05, ** p,0.01, ***p,0.001
doi:10.1371/journal.pone.0000177.g006
Figure 7. Effect of inhibition of PI3K, ERK and JNK pathways on PAI and
uPA activity. uPA enzyme activity was assessed by casein zymography,
and PAI activity determined by reverse casein zymography in cell
lysates from untreated control cells (C), cells treated with 10 ng/mL
TGFb alone (T) and in cells treated with TGFb and PI3K inhibitor
LY294002 (LY), ERK inhibitor PD98059 (PD) or JNK inhibitor SP600125
(SP) for 24 h. uPA activity was detected as digested clear bands on
a dark background, whilst PAI activity was detected as dark undigested
bands against a clear background.
doi:10.1371/journal.pone.0000177.g007
Table 1. Summary of the invasive characteristics of the cell
lines
......................................................................
Cell line Origin Aggregation Invasion Wounding
OE33 BE Adenoca. 3.3, p,0.05 1.5, p,0.05 1.3, p,0.01
TE7 BE Adenoca. 1.3, p,0.01 2.0, p,0.05 2
SEG BE Adenoca. 2.2, p,0.01 22
FLO BE Adenoca. 1.6, p,0.05 22
+ Denotes induction of a more invasive phenotype namely an increase in
wounding, a reduction in aggregation and an increase in invasion following
TGFb stimulation.
2 Denotes no effect of TGFb on these assays.
The statistical comparison is in relation to the no TGFb control.
doi:10.1371/journal.pone.0000177.t001
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PLoS ONE | www.plosone.org 6 January 2007 | Issue 1 | e177[25,26], while the uPA promoter also contains two AP-1 binding
sites [27]. Targets of the MAPK pathways ERK and JNK include
the transcription factors c-Fos, c-Jun and ATF-2, which can
undergo c-Fos/c-Jun or c-Jun/ATF-2 heterodimerisation to form
AP-1. Activation of MAPK pathways can thus increase the
expression of PAI and uPA [28,29]; however, we cannot rule out
the contribution of other pathways such as matrix metalloprotei-
nases which also contain AP-1 promoter sites and are involved in
ECM remodelling during invasion.
The combination of uPA, uPA receptor and PAI is crucial in
the modulation of ECM homeostasis and tumour invasion as
demonstrated in breast and prostate cancer cells [30,31] and
oesophageal adenocarcinoma cells made to over-express uPA in
vitro [11]. Elevated levels of uPA and PAI can also enhance
migration, through modulation of cell-to-matrix adhesion [7,32].
The involvement of PAI and uPA in invasion may explain the
functional significance of the inhibition of kinase pathways on the
invasive properties of oesophageal adenocarcinoma cells (Figure 8).
It is worth noting that OE33 was the only cell line that had
a demonstrable increase in the SMAD reporter construct as well as
increased kinase activity in response to TGFbl. For this cell line it
is not possible to rule out a contribution of Smad activation in the
TGFbl response of OE33 cells although the invasive properties
were significantly reduced by kinase inhibitors (Figure 8).
uPA and PAI expression through the activity of ERK and JNK
may also be relevant for tumour progression in vivo. For example,
in prostate, breast and pancreatic carcinoma cells, JNK, or the
upstream activator of both kinases, MKK4, has been demonstrat-
ed to mediate growth of cells in vitro, and as xenografts in vivo
[33,34]. Furthermore, over-expression of PAI and uPA has been
shown to correlate strongly with tumour stage and to be of
Figure 8. Effect of inhibition of PI3K, ERK and JNK pathways on invasive properties of oesophageal adenocarcinoma cells following TGFb stimulation.
(A) Aggregation in control cells cultured with normal medium (C), cells treated with TGFb alone (T) or in the presence of PI3K inhibitor LY294002 (LY),
ERK inhibitor PD98590 (PD) or JNK inhibitor SP600125 (SP). Scores represent the mean for 3 separate experiments where 0 is for no aggregates, 1 for
small aggregates and 2 for large aggregates. (B) Invasion assay through matrigel matrix over 24 h in untreated cells (C), treated with TGFb alone (T) or
in the presence of inhibitors (LY, PD or SP), (C) Wound healing measured as the percentage of healing of a circular wound over 24 h was assessed in
OE33 cells cultured in normal medium (C), or with the addition of TGFb (T) or with TGFb in the presence of inhibitors (LY, PD or SP). For all
experiments TGFb is compared with the control and the effect of inhibitors compared with TGFb.*p ,0.05, **p,0.01.
doi:10.1371/journal.pone.0000177.g008
Table 2. Modulation of proliferation and ECM associated
genes by TGFb in oesophageal cells
......................................................................
OE33 TE7 SEG BIC FLO
Inhibition of proliferation + 2222
PAI-1 increase ++ + 2 +
uPA increase ++ + 22
+ significant quantitative change, 2 no significant quantitative change
doi:10.1371/journal.pone.0000177.t002
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noma [13,35].
In conclusion, we have shown that there is a divergent response
to TGFb in cells from BE adenocarcinoma. The Smad dependent
anti-proliferative response is lost; however, the ability of TGFb to
induce ECM genes PAI and uPA prevails. This occurs pre-
dominantly through the ERK and JNK MAPK pathways, and
thus contributes to the invasive properties of the oesophageal
tumour cell. Such a differential response utilising different cell
signalling pathways may allow TGFb to play a role in both the
initiation and progression of oesophageal adenocarcinoma.
MATERIALS AND METHODS
Cell lines and culture conditions
For this study cell lines derived from Barrett’s adenocarcinoma
were used. Barrett’s associated adenocarcinoma cell lines OE33
(European Collection of Cell Cultures, Wiltshire, UK), TE7 (gift
from T Nishihira, Kurokawa County Hospital, Japan), were
maintained in RPMI-1640, and SEG, BIC and FLO (gift from D
Beer, University of Michigan, MI, USA) were maintained in
DMEM. All cells were supplemented with 10% (FBS), 100 U/mL
penicillin, 100 mg/mL streptomycin and 2 mM glutamine.
Kinase inhibition
Cells were grown to 70% confluence in complete medium, which
was then replaced with serum free medium for 3 h. Cells were pre-
treated for 1 h with inhibitors at the minimal concentration
leading to kinase inhibition (data for determining optimal inhibitor
concentrations not shown): PI3K inhibitors - Wortmannin (5 nM)
and LY294002 (20 mM) (Calbiochem-Novabiochem, Nottingham,
UK); ERK inhibitors - U0126 (inhibits MEK 1 and 2), (10 mM)
and PD098059 (inhibits MEK 1), (20 mM) (Sigma-Aldrich, Dorset,
UK); and JNK inhibitors - SP600125 (20 mM) (Sigma-Aldrich)
and curcumin (10 mM) (Calbiochem-Novabiochem). Cells were
then treated with 10 ng/mL TGFb1 for 24 h in the presence of
inhibitors. This concentration was used as we have previously
shown in dose response experiments that it is the optimum
concentration to induce a decrease in proliferation [17].
Flow cytometry
10
4 cells were seeded in 6 well plates in complete growth medium,
and all cells were synchronised overnight in serum-free medium.
Cells were then either incubated in complete medium with or
without 10ng/mL recombinant TGFb1 (Tebu-bio, Cambridge-
shire, UK), or kept in serum free medium, for 24 h. Cells were
harvested, fixed in 70% ethanol at 4uC and then incubated in PBS,
0.1% Tween 20 containing 2 mg/mL propidium iodide (Sigma-
Aldrich) and 200 mg/mL RNAse A for 30 min at 37uC. DNA
content was analysed by fluorescence associated cell sorting
(FACS) using the BD LSR1 flow cytometer (BD Biosciences,
Oxford, UK), and data captured using Cell quest software (BD
Biosciences, Oxford, UK).
Immunofluorescence staining
Cells were seeded overnight onto sterilised coverslips in a 24 well
plate. Media was removed and replaced with fresh media with or
without 10 ng/ml TGFb1. Following a 6 h incubation, media was
removed and the coverslips washed twice in 0.5 ml PBS. The
coverslips were then stained with Smad2/3 antibody (clone E-20,
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) following
a procedure described previously [17].
Luciferase reporter assay
Cells were seeded in 24 well plates at a density of 5610
4 cells/well
and left overnight. Using Fugene6 transfection reagent (Roche
Applied Science, East Sussex, UK) cells were transfected with the
reporter plasmid (CAGA)12-Luc, containing 12 repeats of the
CAGA Smad3/4 binding sequence. Cells were also transfected
with Renilla luciferase reporter plasmid to normalise transfection
efficiency. After 24 h medium was replaced with serum free
medium with or without TGFb1 (10 ng/mL). After a further 24 h
luciferase activity was determined using the Dual Luciferase
Reporter System (Promega, Southampton, UK) in a TD 20/20
Luminometer (Promega).
Quantitative real time PCR
Two micrograms of total RNA isolated using Trizol Reagent
(Invitrogen, Paisley, UK) were reversed transcribed, and 1 mLo f
cDNA was amplified in a 50 ml volume containing 25 mLo f2 6
Quantitect SYBR Green PCR Master Mix (Qiagen, West Sussex,
UK) and 0.2 mM of each primer (Table 3). Triplicate reactions
were performed in a DNA Opticon using the conditions of initial
enzyme activation of 15 mins at 95uC, followed by 30 to 35 cycles
of 10 s at 95uC, 20 s at the annealing temperature and 20 s at
72uC. The melting curve was constructed for each primer to
ensure reaction specificity. Following PCR, the threshold cycle
(CT) was obtained and relative quantities determined compared to
b actin.
Western blotting and immunoprecipitation
Immunoprecipitation was required due to the low sensitivity of
western blotting alone for the phosphorylated forms of AKT, ERK
and JNK. Protein lysates were prepared with ice-cold lysis buffer
(20 mM Tris pH 7.8, 150mM NaCl, 1 mM EDTA, 1% NP40)
containing protease inhibitors (Complete tablet, Roche, Germany).
200 mg of protein was immunoprecipitated with 1 mg ERK1/2
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA), JNK antibody (1:100) (New England Biolabs, Herts, UK)
and Akt antibody (1:1000) (New England Biolabs, Herts, UK).
20mL of immunoprecipitated sample or 50 mg of proteins were
Table 3. Primer sequences
..................................................................................................................................................
Gene Forward Reverse Annealing T (uC)
c-Myc 59-TCAAGAGGCGAACACACAAC-39 59-GGCCTTTTCATTGTTTTCCA-39 58
P21 59-GGAAGACCATGTGGACCTGT-39 59-GGCGTTTGGAGTGGTAGAAA-39 60
PAI-1 59-GAGACAGGCAGCTCGGATTC-39 59-GGCCTCCCAAAGTGCATTAC-39 60
uPA 59-TGTGAGATCACTGGCTTTGG-39 59-ACACAGCATTTTGGTGGTGA-39 59
b-actin 59-TCACCCACACTGTGCCCATCTACGA-39 59-CAGCGGAACCGCTCATTGCCAATGG-39 60
doi:10.1371/journal.pone.0000177.t003
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and transferred to a PVDF membrane (Hybond-P, Amersham
Biosciences, Amersham, UK). Membranes were incubated over-
night at 4uC with the following antibodies: phospho-ERK1/2
(0.1 mg/mL) (Calbiochem-Novabichem), phospho-JNK (1:1000)
(Calbiochem-Novabichem), phospho-Akt (New England Biolabs)
or pSmad2/3 (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA). Membranes were incubated with a 1:10,000 dilution of
peroxidase conjugate secondary IgG antibody (Perbio Science,
Cheshire, UK), and signals detected by chemiluminescence
(ECL, Amersham Biosciences, Amersham, UK).
Zymography and reverse zymography
To assess uPA activity 50 mg of protein lysate were incubated with
non-reducing buffer for 20 min at 37uC, then electrophoresed in
a polyacrylamide gel containing 2 mg/mL a-casein (Sigma-
Aldrich) and 5 mg/mL plasminogen (Sigma-Aldrich). Gels were
washed 2 times for 30 min each in 50 mM Tris-HCl (pH 7.6),
2.5% Triton X-100, incubated for 16 h at 37uC in 50 mM Tris-
HCl (pH 7.6) and then stained for 1 h in a solution of 30%
methanol, 10% acetic acid and 0.5% Coomassie brilliant blue
G250 and de-stained. Urokinase activity was detected as digested
clear bands on a blue background. To determine PAI activity
lysates were subjected to SDS-PAGE in gels containing 2 mg/mL
a-casein, 5 mg/mL plasminogen and 0.8 U/mL human urokinase
(Calbiochem-Novabichem). Gels were then washed and stained as
above. PAI activity was detected as dark undigested bands against
a light background.
Wound healing assay
Cells were grown in a 60 mm dish to confluency, and then
wounded using a hand held engraving drill (Minicraft MB168)
fitted with a cut down 10 mL pipette tip. Wound area was mea-
sured using an eyepiece graticule and calibrated using a haemo-
cytometer grid, at 106 magnification. The wounded monolayer
was washed with PBS, and then cultured in serum free medium,
containing 10 ng/mL TGFb1 alone or with LY294002 (20 mM),
PD98590 (20 mM) or SP600125 (20 mM) for 24 h. The wound
area was again measured, the absolute change in wound size
deduced and the % healing at 24 h then calculated. In each
experiment 8 wounds were made and each experiment was
repeated at least three times.
Invasion assay
Fifty mL of a 10 mg/mL solution of matrigel (BD Biosciences),
containing 25 mg/mL plasminogen was applied to the upper
compartment of a Transwell 24 well insert (BD Biosciences) of
8 mm pore size, and incubated at 37uC. Cells were washed three
times in serum free RPMI, and then 1610
5 cells were resuspended
in 200 ml of serum free RPMI containing 10 ng/mL TGFb1 alone
or with LY294002 (20 mM), PD98590 (20 mM) or SP600125. Cells
were then applied to the upper compartment of the invasion
chamber. In the lower compartment 500 ml of serum containing
medium was added and the cells were then incubated at 37uC for
24 h. Medium was then removed and the cells were then fixed for
20 min in methanol at 220uC. Chambers were stained in
haematoxylin for 1 min and a cotton swab used to remove non-
invasive cells in the upper compartment. Membranes were excised
from the chamber and fixed on a microscope slide. Membranes
were quantified by counting the number of cells that had invaded
the lower chamber in 5 high-power fields.[11]
Slow aggregation assay
100 mL of agar was solidified in 96 well plate formats. Cells were
washed with Moscona’s solution, trypsinised and then resuspended
in serum free media. 2610
4 cells (100 ml) were seeded into each
well and left for 1 h. 100 mL of serum free medium containing
TGFb1 alone or with LY294002 (20 mM), PD98590 (20 mM) or
SP600125 (20 mM). [36] Aggregates, for 10 replicates in three
independent experiments, were scored after 24 h incubation at
37uC, 5% CO2 using an inverted microscope. Replicates were
scored 0 if no aggregates were present, 1 for small aggregates and
2 for large aggregates.
Statistics
The Kruskal-Wallis test was used to compare values between
different data sets, and the Dunn’s Multiple Comparison Test was
used to identify specific differences, using Graphpad Prism
software. A p,0.05 was necessary for statistical significance.
SUPPORTING INFORMATION
Table S1
Found at: doi:10.1371/journal.pone.0000177.s001 (0.04 MB
DOC)
Figure S1 Densitometry analysis of phosphorylated MAPK. The
western blots (as presented in figure 5) were analysed by
densitometry. The data is presented as fold increase in density of
the TGFb treated band compared to the untreated control for
each cell line and each MAPK.
Found at: doi:10.1371/journal.pone.0000177.s002 (10.47 MB
TIF)
Figure S2 Densitometry analysis of uPA and PAI activity. The
zymographies (as presented in figure 7) were analysed by
densitometry. The data is presented as fold increase in density of
the TGFb treated band with inhibitors compared to the TGFb
treated control for each cell line and each MAPK.
Found at: doi:10.1371/journal.pone.0000177.s003 (9.82 MB TIF)
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